Sweet Syndrome Associated With Granulocyte Colony-Stimulating Factor

Bidyasar, Savita; Montoya, Maria E.; Suleman, Kausar; Markowitz, Avi B.

doi:10.1200/jco.2008.16.2933

Cited by 30 publications

(13 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…46 Treatment related terminal myeloid differentiation of AML blasts into mature neutrophils, as described with quizartinib, may explain development of SS in some of our patients after G-CSF, liposomal ATRA and azacitadine treatments. 19, 20, 24, 46 …”

Section: Discussionmentioning

confidence: 99%

Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia

Kazmi

Pemmaraju

Patel

et al. 2015

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Introduction Sweet's syndrome (SS) is associated with hematologic malignancies including acute myeloid leukemia (AML). Methods Patients with AML treated at our institution were reviewed to identify those with SS. Patient characteristics, laboratory values, and cytogenetic and molecular abnormalities were retrospectively reviewed. Results We identified 21 out of 2,178 (1%) AML patients that demonstrated clinical signs and symptoms, and histological features consistent with SS. Eleven patients (52%) were classified as AML with myelodysplasia-related features while three patients had therapy-related AML. Three patients had received treatment with granulocyte colony stimulation factor, one patient liposomal all-trans retinoic acid and two patients received hypomethylating agents prior to development of SS. Cytogenetic analysis revealed diploid karyotype in seven patients (33%), -5/del(5q) in eight patients {38%; three patients had -5/del(5q) as sole abnormality and five patients had -5/del(5q) as part of complex cytogenetics}, and complex cytogenetics in five patients (24%). Gene mutations in fms-related tyrosine kinase-3 (FLT3) gene were identified in seven of 18 evaluable patients (39%), including FLT3 –internal tandem duplication in four patients and FLT3 -D835 tyrosine kinase domain mutation in three patients. Conclusions SS occurs in 1% of AML patients; -5/del(5q) karyotype, FLT3 mutations, and AML with myelodysplasia-related features were more frequent among patients with SS.

show abstract

Section: Discussionmentioning

confidence: 99%

Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia

Kazmi

Pemmaraju

Patel

et al. 2015

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

show abstract

“…Cutaneous lesions in a photodistributed pattern (Walker and Cohen 1996 ) as well as lesions that develop clinical features of necrosis (Fukutoku et al 1994 ) have also been described. Ocular manifestations, characterized by "bilateral conjunctivitis" or "conjunctival lesions," have also been documented in case reports (Bidyasar et al 2008 ;Paydas et al 1993 ).…”

Section: Sweet Syndrome Associated With G-csfmentioning

confidence: 82%

“…It is characterized by the development of fever, arthralgias, and diffuse, erythematous, painful papules, plaques, or nodules found most commonly in the upper extremities (71 %) but may also affect the chest (50 %), head and neck (43 %), lower extremities (36 %), or oral mucous membranes (7 %) (Walker and Cohen 1996 ). Lesions on the face may follow a periorbital or periauricular distribution (Bidyasar et al 2008 ). Cutaneous lesions in a photodistributed pattern (Walker and Cohen 1996 ) as well as lesions that develop clinical features of necrosis (Fukutoku et al 1994 ) have also been described.…”

Section: Sweet Syndrome Associated With G-csfmentioning

confidence: 99%

“…Nuclear features of apoptosis such as karyorrhexis and an absence of vasculitis and pathogenic microbes are typical features (Bidyasar et al 2008 ;Walker and Cohen 1996 ). The histologic differential diagnosis for drug-induced Sweet syndrome includes Sweet syndrome proper, abscess/cellulitis, granuloma faciale, leukemia cutis, lobular neutrophilic panniculitis, rheumatoid neutrophilic dermatitis, and pyoderma gangrenosum (Cohen et al 2007 ).…”

Section: Sweet Syndrome Associated With G-csfmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Hematopathology

2014

View full text Add to dashboard Cite

“…Ethnic differences in patient demographic characteristics may result in such discrepancies. Furthermore, the adverse effects (eg, leukocytosis, leukemia, acute febrile neutrophilic dermatosis [Sweet's syndrome] 28 ) of G-CSF should be evaluated to balance the risks and benefits of prophylactic use of this treatment.…”

Section: Discussionmentioning

confidence: 99%